GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guangzhou Kingmed Diagnostics Group Co Ltd (SHSE:603882) » Definitions » Piotroski F-Score

Guangzhou Kingmed Diagnostics Group Co (SHSE:603882) Piotroski F-Score : 5 (As of Dec. 13, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Guangzhou Kingmed Diagnostics Group Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Guangzhou Kingmed Diagnostics Group Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Guangzhou Kingmed Diagnostics Group Co's Piotroski F-Score or its related term are showing as below:

SHSE:603882' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 8
Current: 5

During the past 12 years, the highest Piotroski F-Score of Guangzhou Kingmed Diagnostics Group Co was 8. The lowest was 3. And the median was 5.


Guangzhou Kingmed Diagnostics Group Co Piotroski F-Score Historical Data

The historical data trend for Guangzhou Kingmed Diagnostics Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guangzhou Kingmed Diagnostics Group Co Piotroski F-Score Chart

Guangzhou Kingmed Diagnostics Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 8.00 5.00 4.00 5.00

Guangzhou Kingmed Diagnostics Group Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 5.00 4.00 5.00

Competitive Comparison of Guangzhou Kingmed Diagnostics Group Co's Piotroski F-Score

For the Diagnostics & Research subindustry, Guangzhou Kingmed Diagnostics Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guangzhou Kingmed Diagnostics Group Co's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guangzhou Kingmed Diagnostics Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Guangzhou Kingmed Diagnostics Group Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 67.365 + -18.637 + 108.287 + 4.189 = ¥161 Mil.
Cash Flow from Operations was 723.009 + -138.311 + 172.593 + 277.633 = ¥1,035 Mil.
Revenue was 2230.006 + 1841.261 + 2039.645 + 1737.946 = ¥7,849 Mil.
Gross Profit was 752.709 + 590.81 + 758.114 + 626.332 = ¥2,728 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(12163.052 + 11767.672 + 11602.333 + 11301.883 + 10978.237) / 5 = ¥11562.6354 Mil.
Total Assets at the begining of this year (Sep23) was ¥12,163 Mil.
Long-Term Debt & Capital Lease Obligation was ¥572 Mil.
Total Current Assets was ¥7,603 Mil.
Total Current Liabilities was ¥2,321 Mil.
Net Income was 306.444 + 149.613 + 135.23 + 291.174 = ¥882 Mil.

Revenue was 3268.161 + 2117.566 + 2190.945 + 2001.11 = ¥9,578 Mil.
Gross Profit was 1202.959 + 802.92 + 867.687 + 691.775 = ¥3,565 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(13913.229 + 13892.733 + 13409.37 + 12231.092 + 12163.052) / 5 = ¥13121.8952 Mil.
Total Assets at the begining of last year (Sep22) was ¥13,913 Mil.
Long-Term Debt & Capital Lease Obligation was ¥447 Mil.
Total Current Assets was ¥8,602 Mil.
Total Current Liabilities was ¥2,947 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Guangzhou Kingmed Diagnostics Group Co's current Net Income (TTM) was 161. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Guangzhou Kingmed Diagnostics Group Co's current Cash Flow from Operations (TTM) was 1,035. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=161.204/12163.052
=0.01325358

ROA (Last Year)=Net Income/Total Assets (Sep22)
=882.461/13913.229
=0.06342604

Guangzhou Kingmed Diagnostics Group Co's return on assets of this year was 0.01325358. Guangzhou Kingmed Diagnostics Group Co's return on assets of last year was 0.06342604. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Guangzhou Kingmed Diagnostics Group Co's current Net Income (TTM) was 161. Guangzhou Kingmed Diagnostics Group Co's current Cash Flow from Operations (TTM) was 1,035. ==> 1,035 > 161 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=572.297/11562.6354
=0.04949538

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=447.198/13121.8952
=0.03408029

Guangzhou Kingmed Diagnostics Group Co's gearing of this year was 0.04949538. Guangzhou Kingmed Diagnostics Group Co's gearing of last year was 0.03408029. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=7602.529/2320.85
=3.27575199

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=8602.263/2946.558
=2.91942768

Guangzhou Kingmed Diagnostics Group Co's current ratio of this year was 3.27575199. Guangzhou Kingmed Diagnostics Group Co's current ratio of last year was 2.91942768. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Guangzhou Kingmed Diagnostics Group Co's number of shares in issue this year was 463.899. Guangzhou Kingmed Diagnostics Group Co's number of shares in issue last year was 471.007. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2727.965/7848.858
=0.34756203

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3565.341/9577.782
=0.37225122

Guangzhou Kingmed Diagnostics Group Co's gross margin of this year was 0.34756203. Guangzhou Kingmed Diagnostics Group Co's gross margin of last year was 0.37225122. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=7848.858/12163.052
=0.64530333

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=9577.782/13913.229
=0.6883939

Guangzhou Kingmed Diagnostics Group Co's asset turnover of this year was 0.64530333. Guangzhou Kingmed Diagnostics Group Co's asset turnover of last year was 0.6883939. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Guangzhou Kingmed Diagnostics Group Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Guangzhou Kingmed Diagnostics Group Co  (SHSE:603882) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Guangzhou Kingmed Diagnostics Group Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Guangzhou Kingmed Diagnostics Group Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Guangzhou Kingmed Diagnostics Group Co Business Description

Traded in Other Exchanges
N/A
Address
International Biological Island spiral three on the 10th, Guangdong Province, Guangzhou, CHN, 510000
Founded in 1994, KingMed is the largest independent clinical laboratory in China. It was listed on the Shanghai Stock Exchange in 2017. As of 2023, KingMed has 49 centralized labs and provides over 4000 test items. Over 90% of its total revenue comes from clinical diagnostics. Furthermore, KingMed has been actively investing in its cold chain logistics. Its service network covers the most intensely populated areas in China.
Executives
Hao Bi Xi Directors, senior managers
Wang Ling Lai Director
Yu Shi Hui senior management
Liang Yao Ming Director
Peng Yong Xiang Director

Guangzhou Kingmed Diagnostics Group Co Headlines

No Headlines